We recently reported the radiosynthesis and in vitro evaluation of [18F]-2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-(2-fluoroethoxy)benzyl)ethanamine, ([18F]FECIMBI-36) or ([18F]1), an agonist radioligand for 5HT2A/2Creceptors in postmortem samples of human brain. Herein we describe the in vivo evaluation of [18F]FECIMBI-36 in vervet/African green monkeys by PET imaging. PET images show that [18F]FECIMBI-36 penetrates the blood-brain barrier and a low retention of radioactivity is observed in monkey brain. Although the time activity curves indicate a somehow heterogeneous distribution of the radioligand in the brain, the low level of [18F]FECIMBI-36 in brain may limit the use of this tracer for quantification of 5-HT2A/2Creceptors by PET.
CITATION STYLE
Prabhakaran, J., Solingapuram Sai, K. K., Zanderigo, F., Rubin-Falcone, H., Jorgensen, M. J., Kaplan, J. R., … Kumar, J. S. D. (2017). In vivo evaluation of [18F]FECIMBI-36, an agonist 5-HT2A/2Creceptor PET radioligand in nonhuman primate. Bioorganic and Medicinal Chemistry Letters, 27(1), 21–23. https://doi.org/10.1016/j.bmcl.2016.11.043
Mendeley helps you to discover research relevant for your work.